Baricitinib plus remdesivir reduces time to recovery in COVID-19 patients in NIAID-sponsored ACTT-2 trial

Baricitinib plus remdesivir reduces time to recovery in COVID-19 patients in NIAID-sponsored ACTT-2 trial. (Credit: Pete Linforth from Pixabay)